Go to the list of all blogs
Niko Sharks's Avatar
published in Blogs
Mar 28, 2019
TickeronGET DAILY SIGNALS
Walgreens (WBA, $62.59) to sell CBD products in over 1,500 stores in the U.S.

Walgreens (WBA, $62.59) to sell CBD products in over 1,500 stores in the U.S.

The second-largest pharmacy store chain of U.S., Walgreens will sell CBD or cannabis-based products like creams, patches, and sprays in over its 1,500 stores in select states of U.S. like Oregon, Colorado, New Mexico, Kentucky, Tennessee, Vermont, South Carolina, Illinois and Indiana. The products so far will be limited to health and wellbeing services.

Walgreens’s venture into CBD products is not unprecedented as rivals like CVS had already introduced CBD-containing topicals, including creams and salves, to stores in eight U.S. states earlier in March. Walgreens now joins retailers who are carefully evaluating the market for cannabis-based products.

According to the company, the market is fairly nascent with much to test and explore. Though consumers are curious about cannabis-based products and their promise to heal everything from depression to anxiety, studies are yet to confirm such observations.

Thanks to the farm bill Congress passed late last year, CBD derived from hemp is now legal, but FDA is yet to approve of CBD additions to food or sell it as a dietary supplement.

Even though there is much to be explored in this segment, selling CBD-infused beauty and skin-care products brings far less risk, thus making it the obvious first step for retailers keen on exploring cannabis’ potential.

Related Ticker: WBA
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of drug store services

Industry DrugstoreChains

Industry
Drugstore Chains
Address
108 Wilmot Road
Phone
+1 847 315-3700
Employees
331000
Web
https://www.walgreensbootsalliance.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
Nebius Group N.V. is expected to report third-quarter 2026 results in early November, following a second quarter in which revenue surged 454% year over year. Wall Street consensus tracked by Benzinga points to roughly $937 million in Q3 2026 revenue, up from $146.1 million in the year-ago quarter.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
Walgreens (WBA, $62.59) to sell CBD products in over 1,500 stores in the U.S.